Roivant Sciences Ltd.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Roivant Sciences develops and commercializes drugs by creating and operating subsidiary companies ("Vants"), each focused on advancing a specific medicine or technology through clinical development and, if approved, to market. The company's pipeline spans areas such as immunology, gastroenterology, and rare diseases, with subsidiaries often licensing drug candidates from larger pharmaceutical companies for further development.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Venker EricPresident & Immunovant CEO | Sell | $5.92M | 166,182at $35.63 | Aug 28, 2026 |
| Venker EricPresident & Immunovant CEO | Sell | $1.23M | 33,818at $36.44 | Aug 28, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $6.43M | 172,899at $37.17 | Aug 19, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $5.28M | 144,756at $36.48 | Aug 21, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $653K | 17,519at $37.30 | Aug 20, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $3.85M | 105,141at $36.59 | Aug 18, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $8.81M | 243,177at $36.23 | Aug 14, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $1.18M | 31,801at $37.18 | Aug 18, 2026 |
| Sukhatme MayukhPresident & CIO | Sell | $10.32M | 284,707at $36.25 | Aug 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ROIV activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.